We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Honda (HMC) Operating Profit Decreases Roughly 67% Y/Y in Q4
Read MoreHide Full Article
Honda Motor Co., Ltd. (HMC - Free Report) has reported operating profit of ¥42.4 billion in the fourth quarter of fiscal 2019, down 66.6% from the year-ago period. This decrease in operating profit can be attributed to the adverse foreign currency effects and impact of changes in the global automobile production network and capability on Europe. These negative factors were partly offset by continuous cost-reduction efforts.
In the reported quarter, profit before income taxes decreased by 41.7% to ¥111.1 billion. Loss per share attributable to owners of the parent was ¥7.4, marking a decline of ¥67.99 from the year-ago figure.
Revenues increased 3.4% year over year to ¥4.05 trillion. This rise can be attributed to higher sales revenues at automobile and financial services businesses.
Honda Motor Co., Ltd. Price, Consensus and EPS Surprise
For the three months ended Mar 31, 2019, revenues from the Automobile segment increased 2.9% to ¥2.84 trillion. During the reported quarter, consolidated units sold increased 3.1% year over year to 0.98 million.
The Motorcycle segment’s revenues decreased 6.1% to ¥489.4 billion and consolidated units sold increased 10.4% year over year to 2.84 million.
During the reported quarter, the Life Creation segment’s consolidated units sold decreased 5.2% year over year to 2.34 million.
Financial Position
Consolidated cash and cash equivalents were ¥2.49 trillion as of Mar 31, 2019, up from ¥2.26 trillion as of Mar 31, 2018.
As of Mar 31, 2019, Honda’s net cash from operating activities amounted to ¥776 billion compared with the year-ago figure of ¥987.7 billion. This decline in the number was due to increased expenses for parts and raw materials, partly offset by cash received from customers.
Dividend Payment
The company announced a quarterly dividend of ¥28 per share for shareholders. For fiscal 2019, the total annual dividend payment per share is ¥111.
Guidance
Honda provided financial estimates for fiscal 2020 (ending Mar 31, 2020). At the end of fiscal 2020, this Japanese automaker expects revenues to decline 1.2% year over year to ¥15.7 trillion. Further, operating income is likely to increase 6% to ¥770 billion. Earnings per share at the end of fiscal 2020 are expected to be ¥377.94.
Zacks Rank & Stocks to Consider
Honda currently has a Zacks Rank #4 (Sell). A few better-ranked stocks in the auto space are AB Volvo (VLVLY - Free Report) , Fox Factory Holding Corp. (FOXF - Free Report) and Geely Automobile Holdings Ltd. (GELYY - Free Report) . While Volvo currently sports a Zacks Rank #1 (Strong Buy), Fox Factory and Geely carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Volvo has an expected long-term growth rate of 5%. Over the past three months, shares of the company have gained 4.7%.
Fox Factory has an expected long-term growth rate of 16.4%. Over the past three months, shares of the company have gained 21.1%.
Geely Automobile has an expected long-term growth rate of 7%. Share price of the company has increased 3.5% in the past three months.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Honda (HMC) Operating Profit Decreases Roughly 67% Y/Y in Q4
Honda Motor Co., Ltd. (HMC - Free Report) has reported operating profit of ¥42.4 billion in the fourth quarter of fiscal 2019, down 66.6% from the year-ago period. This decrease in operating profit can be attributed to the adverse foreign currency effects and impact of changes in the global automobile production network and capability on Europe. These negative factors were partly offset by continuous cost-reduction efforts.
In the reported quarter, profit before income taxes decreased by 41.7% to ¥111.1 billion. Loss per share attributable to owners of the parent was ¥7.4, marking a decline of ¥67.99 from the year-ago figure.
Revenues increased 3.4% year over year to ¥4.05 trillion. This rise can be attributed to higher sales revenues at automobile and financial services businesses.
Honda Motor Co., Ltd. Price, Consensus and EPS Surprise
Honda Motor Co., Ltd. Price, Consensus and EPS Surprise | Honda Motor Co., Ltd. Quote
Segmental Performance
For the three months ended Mar 31, 2019, revenues from the Automobile segment increased 2.9% to ¥2.84 trillion. During the reported quarter, consolidated units sold increased 3.1% year over year to 0.98 million.
The Motorcycle segment’s revenues decreased 6.1% to ¥489.4 billion and consolidated units sold increased 10.4% year over year to 2.84 million.
During the reported quarter, the Life Creation segment’s consolidated units sold decreased 5.2% year over year to 2.34 million.
Financial Position
Consolidated cash and cash equivalents were ¥2.49 trillion as of Mar 31, 2019, up from ¥2.26 trillion as of Mar 31, 2018.
As of Mar 31, 2019, Honda’s net cash from operating activities amounted to ¥776 billion compared with the year-ago figure of ¥987.7 billion. This decline in the number was due to increased expenses for parts and raw materials, partly offset by cash received from customers.
Dividend Payment
The company announced a quarterly dividend of ¥28 per share for shareholders. For fiscal 2019, the total annual dividend payment per share is ¥111.
Guidance
Honda provided financial estimates for fiscal 2020 (ending Mar 31, 2020). At the end of fiscal 2020, this Japanese automaker expects revenues to decline 1.2% year over year to ¥15.7 trillion. Further, operating income is likely to increase 6% to ¥770 billion. Earnings per share at the end of fiscal 2020 are expected to be ¥377.94.
Zacks Rank & Stocks to Consider
Honda currently has a Zacks Rank #4 (Sell). A few better-ranked stocks in the auto space are AB Volvo (VLVLY - Free Report) , Fox Factory Holding Corp. (FOXF - Free Report) and Geely Automobile Holdings Ltd. (GELYY - Free Report) . While Volvo currently sports a Zacks Rank #1 (Strong Buy), Fox Factory and Geely carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Volvo has an expected long-term growth rate of 5%. Over the past three months, shares of the company have gained 4.7%.
Fox Factory has an expected long-term growth rate of 16.4%. Over the past three months, shares of the company have gained 21.1%.
Geely Automobile has an expected long-term growth rate of 7%. Share price of the company has increased 3.5% in the past three months.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>